secwatch.observer — SEC 8-K summary
======================================

Issuer:     T2 Biosystems, Inc. (—)
CIK:        0001492674
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173928
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

T2 Biosystems receives Nasdaq bid price deficiency notice; faces potential delisting
--------------------------------------------------------------------------------

- Received Nasdaq deficiency letter on June 20, 2023 for bid price below $0.10/share for 10 consecutive days.
- Also previously non-compliant with MVLS minimum $35M; hearing scheduled for July 6, 2023.
- Company plans to present compliance plan to Nasdaq, including potential reverse stock split.
- No assurance of continued listing; delisting risk remains if plan not accepted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492674/000119312523173928/0001193125-23-173928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492674/000119312523173928/d504829d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer